Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
September 05, 2023 07:59 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
La 2ème partie de l’essai clinique de Phase II de DNV3837 dans les infections à Clostridioïdes difficile sera étendue au Canada
April 07, 2022 11:45 ET
|
Deinove
La 2ème partie de l’essai clinique de Phase II de DNV3837 dans les infections à Clostridioïdes difficile sera étendue au Canada L’extension de l’essai clinique au Canada permettra d’ajouter de 5...
The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada
April 07, 2022 11:45 ET
|
Deinove
The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada The extension of the clinical trial in Canada will add 5 new sites to those...
Issuance of 2nd tranche of €500,000 of notes convertibles into new shares
December 15, 2021 11:45 ET
|
Deinove
Issuance of 2nd tranche of €500,000 of notes convertibles into new shares DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial...
Émission d’une 2ème tranche d’OC de 500.000€
December 15, 2021 11:45 ET
|
Deinove
Émission d’une 2ème tranche d’OC de 500.000€ DEINOVE renforce sa trésorerie pour financer son besoin en fonds de roulement et la poursuite de l’essai clinique de Phase II évaluant DNV3837 dans les...
DNV3837 antibiotic candidate: the Phase II trial continues in the US
July 15, 2020 12:30 ET
|
Deinove
DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak DEINOVE (Euronext Growth Paris: ALDEI), a French biotech...
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections
January 27, 2020 01:30 ET
|
Deinove
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837...
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837
May 16, 2019 12:30 ET
|
Deinove
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837 Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic...